Budget Impact Analysis of The Inclusion of Tofacitinib In The Public List of Reimbursement In The Treatment of Rheumatoid Arthritis After Inadequate Response To Methotrexate In Colombia
May 1, 2015, 00:00
10.1016/j.jval.2015.03.912
https://www.valueinhealthjournal.com/article/S1098-3015(15)00969-9/fulltext
Title :
Budget Impact Analysis of The Inclusion of Tofacitinib In The Public List of Reimbursement In The Treatment of Rheumatoid Arthritis After Inadequate Response To Methotrexate In Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00969-9&doi=10.1016/j.jval.2015.03.912
First page :
A157
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
354